Top Markets
Coin of the day
Sensorion SA Sensorion SA

Sensorion SA

ALSEN
Rang in aandelen #13314
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug... Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.
Aandeelprijs
$0.30780727
Marktkapitalisatie
$94.19M
Verandering (1 dag)
-0.19%
Verandering (1 jaar)
-34.73%
Land
FR
Handel Sensorion SA (ALSEN)

Categorie

Dividendgeschiedenis van Sensorion SA (ALSEN)
Sensorion SA (aandelsymbool: ALSEN) heeft in totaal 0 dividenduitkeringen gedaan.
De som van alle dividenden (aangepast voor aandelensplitsingen) is: 0.00
Dividendrendement (TTM): 0
Dividendbetalingen voor Sensorion SA (ALSEN) van 2026 tot 2026
Jaarlijkse dividendbetalingen
Jaar Dividend (aangepast voor aandelensplitsingen) Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Lijst van alle dividendbetalingen
Jaar Dividend Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendbetalingen voor vergelijkbare bedrijven of concurrenten
Bedrijf Aantal dividendbetalingen Land
52.00%
DK
0.00%
US
5.00%
US
29.00%
BE
0.00%
NL